Published research
The Eyerising Myopia Management Device has been validated by an extensive clinical trial program, with numerous peer-reviewed publications in leading journals demonstrating its efficacy and safety in the treatment of myopia. Below, you can find summaries of our key clinical papers. As new literature is constantly being published on repeated low-level red-light therapy, we also offer updates regarding new pertinent articles on our News page. For any other enquiries on our clinical evidence, ongoing and future research, please contact info@eyerisinginternational.com.
The Eyerising Myopia Management Device has been validated by an extensive clinical trial program, with many research publications from leading ophthalmology and optometry journals.
In particular, our landmark trial demonstrated that higher treatment compliance leads to higher treatment effect, with up to 87.7% efficacy in controlling myopia where children were >75% compliant with the treatment protocol.
We encourage you to speak to your eye care professional to discuss further the scientific literature underpinning repeated low-level red-light therapy. Should they have any further questions, please direct them to info@eyerisinginternational.com.
How the Eyerising Myopia Management Device works
In a normal eye, light passes through the lens with the focal point correctly reaching the retina.
In a normal eye, light passes through the lens with the focal point correctly reaching the back of the eye, known as the retina.
As myopia progresses, the length of the eye, known as the axial length, increases, which means that the focal point of light entering the eye falls in front of the retina. Continued axial lengthening and further focal point misalignment leads to high myopia.
As myopia progresses, axial lengthening and focal point mis-alignment increase. Continued axial lengthening and focal point misalignment leads to high myopia.
The Eyerising Myopia Management Device delivers Repeated Low-Level Red-Light therapy to the back of the eye, where it can stimulate blood flow and thicken the outer layer of the back of the eye known as the choroid. This helps to slow further elongation of the eye’s axial length and thereby control myopia progression.
The device delivers Repeated Low-Level Red-Light therapy to the ocular fundus.
Blood flow is stimulated and increases to rethicken the choroid layer to help slow the axial length’s further elongation and control myopia’s progression.
See reference (1)
See reference (2)
Extensive clinical trial program
An extensive clinical trial program has proven the effectiveness of using the Eyerising Myopia Management Device for reducing the progression of myopia for up to 2 years.
To find out more or to obtain copies of some of our key scientific publications, please contact us on: info@eyerisinginternational.com
Extensive clinical trial program
An extensive clinical trial program has established the impressive effectiveness and safety of using Repeated Low-Level Red-Light (RLRL) therapy and the Eyerising Myopia Management Device for the treatment of myopia. In addition to the six peer-reviewed clinical papers located in the Science Hub, there are currently multi-ethnic clinical trials underway in Australia and the USA and high and adult myopia clinical trials underway in Japan.
Achieving up to 87.7% myopia control efficacy when patient has >75% compliance¹
Overall, children in the RLRL-plus-spectacles group had a 76.6% reduction in myopia progression compared with children in the single vision spectacles-only group (SVS). There was an 87.7% reduction in children who had high compliance with the treatment schedule (>75%). There were no known significant side effects, and the overall, the treatment was well tolerated by the children participating in the trial.
At the end of this study, the participants were invited to enrol in a follow-up study for a further 12 months.2 Those children who continued with RLRL therapy had a 75% reduction in myopia progression, and those who switched to RLRL therapy in the second year had a 31% reduction in myopia progression when compared with those children who stayed with SVS. Visual acuity remained the same with no known side effects or severe adverse events.
Ongoing research
We have ongoing clinical trials and real-world studies in Melbourne (Australia), Tokyo (Japan), San Francisco (USA), Madrid (Spain) and pan-Europe (France, Germany, Italy, Spain, Poland, Norway, Portugal). Our studies in San Francisco (USA), Paris (France), Porto (Portugal), Olzstyn (Poland) and Oslo (Norway) are presently recruiting.
To find out more, please contact info@eyerisinginternational.com.
We also have 5 ongoing clinical trials and real-world studies outside of China. These include randomised controlled trials at the Australian College of Optometry (Australia) on multi-ethnic efficacy, Tokyo Medical and Dental University (Japan) on high myopia in children and choroidal thickening in adults, University of California San Francisco (USA) on multi-ethnic efficacy, and Centro De Miopia Fernandez Velazquez (Spain) on adjunct use of RLRL with orthokeratology. Additionally, our Europe real-world study is involving participants across 7 European countries to examine the efficacy of RLRL in Caucasian populations.
Promising interim results are also available from our Australian, Japanese and Spanish trials. For more information, please contact info@eyerisinginternational.com. We look forward to the publication of both full manuscripts in due course.
Future research
At Eyerising International, we recognise how pivotal clinical research is to our story and greatly value our research collaborations. We welcome all external suggestions of investigator-initiated protocols, as well as joint research ventures.
Should you or your colleagues be interested in working with us, please contact info@eyerisinginternational.com to be put in contact with our clinical team.
References
1. Jiang Y, Zhu Z, Tan X et al. Effect of Repeated Low-Level Red-Light therapy for myopia control in children. Ophthalmology 2022; 129 (5): 509–519.
2. Xiong R, Zhu Z, Jiang Y et al. Sustained and rebound effect of Repeated Low-Level Red-Light therapy on myopia control: a 2-year post-trial follow-up study. Clinical & Experimental Ophthalmology 2022 (August); published online ahead of print. 3. Dong J, Zhu Z, Xu H et al. Myopia control effect of Repeated Low-Level Red-Light therapy in Chinese children: a randomized, double-blind, controlled clinical trial. Ophthalmology 2022 (August); published online ahead of print.
3. Compliance report IEC 60601-1-2:2014 4. CFDA website: https://www.nmpa.gov.cn/
5. Xiong, Ruilin, et al. “Longitudinal changes and predictive value of choroidal thickness for myopia control following Repeated Low-Level Red-Light therapy.” Ophthalmology (2022).
6. Dong, Jing, et al. “Myopia Control Effect of Repeated Low-Level Red-Light Therapy in Chinese Children: A Randomized, Double-Blind, Controlled Clinical Trial.” Ophthalmology (2022).
